NYSE: GKOS · Industrial Applications and Services · 8 alerts · CIK 1192448
Share price
$244.88Close, Nov 16
Market cap
$14.5B
Shares outstanding
59.2MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Glaukos Corp filings on SEC EDGAR ↗
Glaukos President & COO Joseph E. Gilliam Sells $11.1M of Stock
Joseph E. Gilliam, President & COO, sold 44,917 shares of Glaukos Corp at $243.41 to $248.42 a share (average $246.32) in 6 transactions, worth $11.1M in total on Nov 12, 2026. Shares held after the trade: 71,602 (-0.4%).
Glaukos Corporation filed a formal investor presentation dated November 2026 to be used in meetings with investors and stakeholders. The presentation covers the company's strategic outlook, including the commercialization of its iDose TR and Epioxa therapies.
Glaukos Director Gilbert H. Kliman Sells $632K of Stock
Gilbert H. Kliman, Director, sold 2,500 shares of Glaukos Corp at $253.00 a share, worth $632K in total on Nov 4, 2026. Shares held after the trade: 37,406 (-6.3%).
Glaukos Chief Development Officer Tomas Navratil Sells $10.6M of Stock
Tomas Navratil, Chief Development Officer, sold 44,436 shares of Glaukos Corp at $237.54 to $240.52 a share (average $238.97) in 4 transactions, worth $10.6M in total on Oct 30, 2026. Shares held after the trade: 37,328 (-14.7%).
Glaukos Corporation reported total assets of $979.5 million as of September 30, 2026, an increase from $893.5 million at year-end 2025, driven largely by growth in cash and accounts receivable. The company remains a large accelerated filer with 59,196,870 shares of common stock outstanding as of October 26, 2026.
Glaukos Corporation reported record third-quarter 2026 net sales of $211.0 million, a 58% increase year-over-year, driven by strong performance in its U.S. Glaucoma and Corneal Health segments. The company achieved GAAP net income of $2.0 million and significantly raised its full-year 2026 revenue guidance while introducing a preliminary 2027 revenue target of $1 billion.
Term
Q3 2026
“Our record third quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers in iDose TR and Epioxa.”
Thomas Burns, Glaukos chairman and chief executive officer